Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Trends & Forecasts

Business & Regulation Trends & Forecasts

How COVID-19 Saved Pfizer’s Revenue

| Stephanie Sutton | 3 min read

Our animated chart illustrates Pfizer’s changing fortunes – and the significant contribution its COVID-19 efforts have made to revenues.

Business & Regulation Trends & Forecasts

Kyiv: Escape and Return

Ukrainian drug discovery has been disrupted by war. We spoke to leaders of its largest player about the domestic industry’s past, present, and future.

Discovery & Development Clinical Trials

Data Damage

| Angus Stewart

The war in Ukraine has massively impacted clinical trials. We spoke to one man tracking the disruption.

Business & Regulation Biosimilars

Brace for Biosimilars!

| Jeff Baldetti

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

Business & Regulation Trends & Forecasts

March’s Top Biopharma Headlines

| Stephanie Sutton

The Medicine Maker’s round up of the top news stories in the pharma industry in March.

Discovery & Development Drug Discovery

A Little Byte of Life

Thorben Seeger wants to democratize the data held by the world’s leading genomic institutions. But what exactly does he mean by “democratize”?

Business & Regulation Profession

Thursday is the Deadline

Nominations and voting for the Power List, Company of the Year Awards, and Innovation Awards ends on Thursday 17 March

Business & Regulation Digital Technologies

Mapping Biochemistry’s Dark Matter: Lessons Learned With Viswa Colluru

| Viswa Colluru

Enveda Biosciences Founder Viswa Colluru shares the lessons he has learned whilst charting the vast terra incognita of nature’s chemical structure

Manufacture Digital Technologies

Industry 4.0: The Invisible Hand

| Angus Stewart

Yvonne Duckworth lays out insights into Pharma 4.0 gleaned in a recent report by CRB. VR, AR, AI: is it more than just alphabet soup?

Discovery & Development Business Practice

“We Want to Return to the Lab”: How the Russian Invasion Has Disrupted Drug Discovery in Ukraine

| Angus Stewart

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.


Latest White Papers

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

All White Papers

Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register